ClinicalTrials.gov
public full text
Public Domain
A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19
Lung surfactant is present in the lungs. It covers the alveolar surface where it reduces the work of breathing and prevents the lungs from collapsing. In some respiratory diseases and in patients that require ventilation this substance does not function normally. This study will introduce surfactant to the patients lungs via the COVSurf Drug Delivery System
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Surfactant Levels in the Lungs of COVID-19 Patients#911435
- Efficacy Evaluation of Surfactant Administration Via Laryngeal Mask Airway#898377
- Surfactant Administration Methods in Preterm Infants With RDS: A Swedish Cohort Study#991922
- Comparison of INRECSURE and LISA in Preterm Neonates With RDS#1173259
- A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study#1112730
Record · ID 890705
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive